A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

被引：0
作者：
Gary H. Lyman
Stephanie J. Green
Peter M. Ravdin
Charles E. Geyer
Christy A. Russell
Stanley P. Balcerzak
G. Thomas Budd
Silvana Martino
机构：
[1] University of Rochester Medical Center,James P. Wilmot Cancer Center
[2] University of Rochester School of Medicine,undefined
[3] Strong Memorial Hospital,undefined
[4] Southwest Oncology Group Statistical Center,undefined
[5] University of Texas Health Science Center,undefined
[6] University of Southern California,undefined
[7] Ohio State University,undefined
[8] Cleveland Clinic,undefined
[9] John Wayne Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2004年 / 85卷
关键词：
doxorubicin; metastatic breast cancer; paclitaxel; phase II; SWOG;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial.
引用
收藏
页码：143 / 150
页数：7
相关论文
共 50 条
  • [21] A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer
    Paridaens, R
    Van Aelst, F
    Georgoulias, V
    Samonnig, H
    Cocquyt, V
    Zielinski, C
    Hausmaninger, H
    Willemse, P
    Boudraa, Y
    Wildiers, J
    Ramazeilles, C
    Azli, N
    ANNALS OF ONCOLOGY, 2003, 14 (03) : 433 - 440
  • [22] A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy
    Rosati, G
    Riccardi, F
    Tucci, A
    De Rosa, P
    Pacilio, G
    TUMORI, 2000, 86 (03) : 207 - 210
  • [23] A phase II trial of a histamine antagonist (DPPE) and doxorubicin in metastatic breast cancer
    de Boer R.
    Breast Cancer Research, 2 (1)
  • [24] Weekly paclitaxel in metastatic breast cancer patients: A phase II study
    Gori, S
    Mosconi, AM
    Basurto, C
    Cherubini, R
    De Angelis, V
    Tonato, M
    Colozza, M
    TUMORI, 2002, 88 (06) : 470 - 473
  • [25] A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
    Perez, EA
    Hillman, DW
    Stella, PJ
    Krook, JE
    Hartmann, LC
    Fitch, TR
    Hatfield, AK
    Mailliard, JA
    Nair, S
    Kardinal, CG
    Ingle, JN
    CANCER, 2000, 88 (01) : 124 - 131
  • [26] Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
    Minish M. Jain
    Smita U. Gupte
    Shekhar G. Patil
    Anand B. Pathak
    Chetan D. Deshmukh
    Niraj Bhatt
    Chiramana Haritha
    K. Govind Babu
    Shailesh A. Bondarde
    Raghunadharao Digumarti
    Jyoti Bajpai
    Ravi Kumar
    Ashish V. Bakshi
    Gouri Sankar Bhattacharya
    Poonam Patil
    Sundaram Subramanian
    Ashok K. Vaid
    Chirag J. Desai
    Ajay Khopade
    Geetanjali Chimote
    Poonamalle P. Bapsy
    Shravanti Bhowmik
    Breast Cancer Research and Treatment, 2016, 156 : 125 - 134
  • [27] Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
    Jain, Minish M.
    Gupte, Smita U.
    Patil, Shekhar G.
    Pathak, Anand B.
    Deshmukh, Chetan D.
    Bhatt, Niraj
    Haritha, Chiramana
    Babu, K. Govind
    Bondarde, Shailesh A.
    Digumarti, Raghunadharao
    Bajpai, Jyoti
    Kumar, Ravi
    Bakshi, Ashish V.
    Bhattacharya, Gouri Sankar
    Patil, Poonam
    Subramanian, Sundaram
    Vaid, Ashok K.
    Desai, Chirag J.
    Khopade, Ajay
    Chimote, Geetanjali
    Bapsy, Poonamalle P.
    Bhowmik, Shravanti
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (01) : 125 - 134
  • [28] First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study
    Elserafi, Mostafa M.
    Zeeneldin, Ahmed A.
    Abdelsalam, Ibrahim M.
    Nassar, Hanan R.
    Moneer, Manar M.
    Buhoush, Wafa H.
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (01) : 13 - 20
  • [29] A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline
    Hong, Ruey-Long
    Lin, Ching-Hung
    Chao, Tsu-Yi
    Kao, Woei-You
    Wang, Cheng-Hsu
    Hsieh, Ruey Kuen
    Hwang, Wei-Shou
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 847 - 853
  • [30] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
12345